Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report
Abstract Hyperprogressive disease (HPD) is a novel progressive pattern that occurs after immune checkpoint inhibitor (ICI) administration. Here, a 74‐year‐old woman who had undergone right lower lobectomy for lung cancer received curative chemoradiotherapy followed by consolidation therapy with durv...
Main Authors: | Kosuke Masuda, Yoshiaki Nagai, Hikari Amari, Hiroki Tahara, Yuki Maeda, Jun Shiihara, Hiromitsu Ohta, Masahiro Hiruta, Yasuhiro Yamaguchi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-11-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.15104 |
Similar Items
-
IFN-γ and CD38 in Hyperprogressive Cancer Development
by: Stefania Angelicola, et al.
Published: (2021-01-01) -
Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer
by: R. Riera-Sala, et al.
Published: (2023-09-01) -
Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
by: Hasan Cagri Yildirim, et al.
Published: (2022-09-01) -
Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics
by: Hugo Arasanz, et al.
Published: (2020-02-01) -
Hyperprogressive Disease: Main Features and Key Controversies
by: Hugo Arasanz, et al.
Published: (2021-04-01)